💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Shalby Limited is an India-based company, which operates multi-specialty hospital chains. Its segments include Healthcare Services segment, which includes the business of setting up and managing hospitals and medical diagnostics services, and Manufacturing segment, which…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A middling, stagnant business, fairly priced.
Shalby is scored on the pharma / healthcare framework. It keeps a thin 3.0% of every rupee of sales as net profit. Cash conversion lags the reported profit (CFO/PAT 0.00×) — worth a closer look. Free cash flow is worth about -7.6% of its market value.
Over the last 3 years revenue compounded at 12%/yr and profit at -20%/yr. Book value has been broadly flat (2.7%/yr). Return on equity is a weak 3.8%. In the latest quarter profit fell 43% versus the prior quarter.
At 37× earnings, the stock sits at the 55th percentile of its own 2.6-year range — the middle of where it has historically traded. Today's price implies ~16%/yr earnings growth for a decade. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 33.53 | 75.46 | better |
| P/B | 1.25 | 3.5 | better |
| EV/EBITDA | 11.03 | 19.83 | better |
| ROE | 3.84 | — | — |
| ROCE | 5.98 | 10.78 | worse |
| ROA | 2.05 | 3.84 | worse |
| Quick Ratio | 0.6 | — | — |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Apollo Hospitals | 52.0 | 11.4 | 21.1% |
| Max Healthcare | 65.9 | 8.0 | 12.2% |
| Manipal Health Enterprises | 93.9 | 5.2 | 10.6% |
Revenue has grown every year across all 4 financial years shown. 12% CAGR over 3 years — steady double-digit compounder. Growth is decelerating — latest year grew slower than the year before.
Revenue is outpacing profit (12% vs -20%) — costs are rising faster than the top line. The latest year saw a +1707% swing — check if it's a one-off or structural.
Operating margin has compressed from 12% to 5% — costs or competition are eating into profitability.
ROE at 3% — modest; the capital isn't working hard.
-20% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
2 of 4 years had negative operating cash flow — profitability on paper may not translate to cash.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue rose 15% sequentially — momentum is building. Run-rate stepping up — recent quarters average 11% above earlier ones.
Profit fell 43% QoQ — one-quarter drops can be noise, but a pattern matters.
How today's P/E compares to the stock's own historical range. Dashed line = the 2.6y median.
Promoters hold 74.3% — heavily owner-operated with strong skin in the game.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.